New Triple-Threat attack on Tough-to-Treat lung cancer
NCT ID NCT07486817
First seen Mar 30, 2026 · Last updated Apr 09, 2026 · Updated 3 times
Summary
This study is testing a new targeted drug, zongertinib, for adults with advanced HER2-mutant lung cancer who haven't had prior treatment. Participants are randomly assigned to receive zongertinib plus standard chemotherapy, or that same combination plus an immunotherapy drug called pembrolizumab. The main goal is to see how safe and tolerable these drug combinations are, while also checking if they help shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CTR Leon Berard
Lyon, 69373, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cabrini Health
Malvern, Victoria, 3144, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangdong Provincial People's Hospital
Guangzhou, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Virgen del Rocío
Seville, 41013, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
INS Curie
Paris, 75005, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kindai University Hospital
Osaka, Sakai, 590-0197, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal North Shore Hospital
St Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
Seoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Severance Hospital
Seoul, 03722, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Geriatric Medical Center
Shanghai, 201104, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Köln (AöR)
Cologne, 50937, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.